08:49 AM EDT, 05/28/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) on Wednesday said it has received approval by the human ethics review committee (HREC) in Australia for its Phase 2 trial assessing its compound FSD202 for treating nociplastic pain associated with idiopathic mast cell activation syndrome.

The trial will run for 56 days and enroll 60 patients with the disorder. The primary outcome to be measured will be the decrease from baseline to Day 28 in the average daily pain intensity.